Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Current Deferred Tax Assets (2016 - 2019)

Historic Current Deferred Tax Assets for Regen BioPharma (RGBPP) over the last 6 years, with Q3 2019 value amounting to $4.2 million.

  • Regen BioPharma's Current Deferred Tax Assets rose 1455.6% to $4.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.2 million, marking a year-over-year increase of 1455.6%. This contributed to the annual value of $4.2 million for FY2019, which is 1455.6% up from last year.
  • As of Q3 2019, Regen BioPharma's Current Deferred Tax Assets stood at $4.2 million, which was up 1455.6% from $3.6 million recorded in Q4 2018.
  • Regen BioPharma's 5-year Current Deferred Tax Assets high stood at $7.7 million for Q4 2016, and its period low was $3.0 million during Q1 2017.
  • Over the past 5 years, Regen BioPharma's median Current Deferred Tax Assets value was $4.2 million (recorded in 2019), while the average stood at $4.6 million.
  • Per our database at Business Quant, Regen BioPharma's Current Deferred Tax Assets soared by 102322.43% in 2015 and then crashed by 4249.84% in 2017.
  • Over the past 5 years, Regen BioPharma's Current Deferred Tax Assets (Quarter) stood at $4.9 million in 2015, then soared by 58.74% to $7.7 million in 2016, then tumbled by 31.75% to $5.3 million in 2017, then plummeted by 31.87% to $3.6 million in 2018, then grew by 16.76% to $4.2 million in 2019.
  • Its Current Deferred Tax Assets was $4.2 million in Q3 2019, compared to $3.6 million in Q4 2018 and $3.7 million in Q3 2018.